Ladan Duvillie

Neuilly-sur-seine, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 8 publications

Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study).

Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study).

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: June 15, 2016

Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.

Clinical use of ferric carboxymaltose in patients with solid tumours or haematological malignancies in France.

Journal: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer

Published: October 22, 2014

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.

Journal: American journal of hematology

Published: June 13, 2014

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.

Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial.

Journal: British journal of haematology

Published: March 31, 2014

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Bosutinib in combination with the aromatase inhibitor exemestane: a phase II trial in postmenopausal women with previously treated locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Journal: The oncologist

Published: March 29, 2014

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Bosutinib in combination with the aromatase inhibitor letrozole: a phase II trial in postmenopausal women evaluating first-line endocrine therapy in locally advanced or metastatic hormone receptor-positive/HER2-negative breast cancer.

Journal: The oncologist

Published: March 29, 2014

High prevalence of iron deficiency in patients with acute decompensated heart failure.

High prevalence of iron deficiency in patients with acute decompensated heart failure.

Journal: European journal of heart failure

Published: February 07, 2014

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.

Bosutinib plus capecitabine for selected advanced solid tumours: results of a phase 1 dose-escalation study.

Journal: British journal of cancer

Published: December 23, 2013

Showing 1-8 of 8

Last Updated: 09/26/2026